Laser-enabled delivery of antiretroviral drugs into HIV-1 infected TZM-bl cells
© 2022 The Authors. Journal of Biophotonics published by Wiley-VCH GmbH..
The use of femtosecond laser to create sub-microscopic transient pores on the cell membrane allowing exogenous material into mammalian cells has become a very efficient optical delivery method over the past decade. This study focuses on laser-enabled delivery of antiretroviral (ARV) drugs into HIV-1 infected TZM-bl cells in vitro. A 1 kHz femtosecond laser emitting at a wavelength of 800 nm was used to photoporate cells at 6.5 μW. Trypan blue was used for characterisation and its uptake was quantified using Matlab software. Cell membrane damage was assessed using the lactate dehydrogenase (LDH) assay while HIV-1 infection was assessed using luciferase assay. Our results showed successful delivery of ARVs into HIV-1 infected cells without compromising their cell membranes, subsequently reducing the level of infection. The LDH assay showed no significant cell membrane damage of laser-treated cells, and the luciferase assay demonstrated significant reduction in the level of HIV-1 infection.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:15 |
|---|---|
| Enthalten in: |
Journal of biophotonics - 15(2022), 10 vom: 19. Okt., Seite e202200043 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Maphanga, Charles [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 05.10.2022 Date Revised 20.10.2022 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1002/jbio.202200043 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM343722100 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM343722100 | ||
| 003 | DE-627 | ||
| 005 | 20231226021119.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1002/jbio.202200043 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1145.xml |
| 035 | |a (DE-627)NLM343722100 | ||
| 035 | |a (NLM)35852044 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Maphanga, Charles |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Laser-enabled delivery of antiretroviral drugs into HIV-1 infected TZM-bl cells |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 05.10.2022 | ||
| 500 | |a Date Revised 20.10.2022 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2022 The Authors. Journal of Biophotonics published by Wiley-VCH GmbH. | ||
| 520 | |a The use of femtosecond laser to create sub-microscopic transient pores on the cell membrane allowing exogenous material into mammalian cells has become a very efficient optical delivery method over the past decade. This study focuses on laser-enabled delivery of antiretroviral (ARV) drugs into HIV-1 infected TZM-bl cells in vitro. A 1 kHz femtosecond laser emitting at a wavelength of 800 nm was used to photoporate cells at 6.5 μW. Trypan blue was used for characterisation and its uptake was quantified using Matlab software. Cell membrane damage was assessed using the lactate dehydrogenase (LDH) assay while HIV-1 infection was assessed using luciferase assay. Our results showed successful delivery of ARVs into HIV-1 infected cells without compromising their cell membranes, subsequently reducing the level of infection. The LDH assay showed no significant cell membrane damage of laser-treated cells, and the luciferase assay demonstrated significant reduction in the level of HIV-1 infection | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a Chinese Hamster ovary cells | |
| 650 | 4 | |a Gaussian beam | |
| 650 | 4 | |a TZM-bl cells | |
| 650 | 4 | |a antiretroviral drugs | |
| 650 | 4 | |a femtosecond laser | |
| 650 | 4 | |a human immunodeficiency virus | |
| 650 | 7 | |a Pharmaceutical Preparations |2 NLM | |
| 650 | 7 | |a Lactate Dehydrogenases |2 NLM | |
| 650 | 7 | |a EC 1.1.- |2 NLM | |
| 650 | 7 | |a Luciferases |2 NLM | |
| 650 | 7 | |a EC 1.13.12.- |2 NLM | |
| 650 | 7 | |a Trypan Blue |2 NLM | |
| 650 | 7 | |a I2ZWO3LS3M |2 NLM | |
| 700 | 1 | |a Manoto, Sello |e verfasserin |4 aut | |
| 700 | 1 | |a Mabena, Chemist |e verfasserin |4 aut | |
| 700 | 1 | |a Ombinda-Lemboumba, Saturnin |e verfasserin |4 aut | |
| 700 | 1 | |a Maaza, Malik |e verfasserin |4 aut | |
| 700 | 1 | |a Mthunzi-Kufa, Patience |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Journal of biophotonics |d 2008 |g 15(2022), 10 vom: 19. Okt., Seite e202200043 |w (DE-627)NLM187619646 |x 1864-0648 |7 nnns |
| 773 | 1 | 8 | |g volume:15 |g year:2022 |g number:10 |g day:19 |g month:10 |g pages:e202200043 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1002/jbio.202200043 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 15 |j 2022 |e 10 |b 19 |c 10 |h e202200043 | ||